Immunovant's total assets for Q2 2026 were $582.96M, a decrease of -11.87% from the previous quarter. IMVT total liabilities were $63.25M for the fiscal quarter, a 19.57% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.